Use of ginseng to reduce post-myocardial adverse myocardial remodeling: Applying scientific principles to the use of herbal therapies

Journal of Molecular Medicine

Volumn 89, Issue 4, 2011, Pages 317-320

  Bodiga, Sreedhar ^a   Wang, Wang ^a   Oudit, Gavin Y ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; ACETYLSALICYLIC ACID; COLLAGEN TYPE 1; CYTOKINE; DIGOXIN; GINSENOSIDE RG 1; MITOGEN ACTIVATED PROTEIN KINASE P38; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; RESERPINE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR 1; TUMOR NECROSIS FACTOR RECEPTOR 2; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR; VASCULOTROPIN;

ANGIOGENESIS; ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; ARTICLE; DIASTOLIC DYSFUNCTION; DRUG ANTAGONISM; ENZYME ACTIVITY; GINSENG; HEART INFARCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE CELL; HEART MUSCLE FIBROSIS; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HEART VENTRICLE REMODELING; HUMAN; NONHUMAN; OXIDATIVE STRESS; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION;

ANIMALS; GINSENOSIDES; HUMANS; PANAX; PHYTOTHERAPY; PLANT PREPARATIONS; VENTRICULAR REMODELING;

EID: 79955780461     PISSN: 09462716     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00109-011-0736-4     Document Type: Article

References (13)

1. Pfeffer MA, Braunwald E (1990) Ventricular remodeling after myocardial infarction. Experimental observations and clinical implications. Circulation 81:1161-1172 (Pubitemid 20119612)
2. De Smet PA (2002) Herbal remedies. N Engl J Med 347:2046-2056 (Pubitemid 35461662)
3. Yin H, Liu Z, Li F, Ni M, Wang B, Qiao Y, Xu X, Zhang M, Zhang J, Lu H, Zhang Y (2011) Ginsenoside-Rg1 enhances angiogenesis and ameliorates ventricular remodeling in a rat model of myocardial infarction. J Molecular Medicine (in press)
4. Oudit GY, Penninger JM (2009) Cardiac regulation by phosphoinositide 3-kinases and PTEN. Cardiovasc Res 82:250-260
5. Sun H, Oudit GY, Ramirez RJ, Costantini D, Backx PH (2004) The phosphoinositide 3-kinase inhibitor LY294002 enhances cardiac myocyte contractility via a direct inhibition of Ik, slow currents. Cardiovasc Res 62:509-520 (Pubitemid 38648965)
6. Leung KW, Pon YL, Wong RN, Wong AS (2006) Ginsenoside- Rg1 induces vascular endothelial growth factor expression through the glucocorticoid receptor-related phosphatidylinositol 3-kinase/Akt and beta-catenin/T-cell factor-dependent pathway in human endothelial cells. J Biol Chem 281:36280-36288 (Pubitemid 46041363)
7. Kassiri Z, Khokha R (2005) Myocardial extra-cellular matrix and its regulation by metalloproteinases and their inhibitors. Thromb Haemost 93:212-219 (Pubitemid 40253724)
8. Jugdutt BI (2010) Preventing adverse remodeling and rupture during healing after myocardial infarction in mice and humans. Circulation 122:103-105
9. Kandalam V, Basu R, Abraham T, Wang X, Soloway PD, Jaworski DM, Oudit GY, Kassiri Z (2010) TIMP2 deficiency accelerates adverse post-myocardial infarction remodeling because of enhanced MT1-MMP activity despite lack of MMP2 activation. Circ Res 106:796-808
10. Hamid T, Gu Y, Ortines RV, Bhattacharya C, Wang G, Xuan YT, Prabhu SD (2009) Divergent tumor necrosis factor receptorrelated remodeling responses in heart failure: role of nuclear factor-kappaB and inflammatory activation. Circulation 119:1386-1397
11. Awad AE, Kandalam V, Chakrabarti S, Wang X, Penninger JM, Davidge ST, Oudit GY, Kassiri Z (2009) Tumor necrosis factor induces matrix metalloproteinases in cardiomyocytes and cardiofi- broblasts differentially via superoxide production in a PI3Kgammadependent manner. Am J Physiol Cell Physiol 298:C679-C692
12. Pouleur AC, Barkoudah E, Uno H, Skali H, Finn PV, Zelenkofske SL, Belenkov YN, Mareev V, Velazquez EJ, Rouleau JL, Maggioni AP, Kober L, Califf RM, McMurray JJ, Pfeffer MA, Solomon SD (2010) Pathogenesis of sudden unexpected death in a clinical trial of patients with myocardial infarction and left ventricular dysfunction, heart failure, or both. Circulation 122:597-602
13. Wang M, Lamers RJ, Korthout HA, van Nesselrooij JH, Witkamp RF, Van Der Heijden R, Voshol PJ, Havekes LM, Verpoorte R, Van Der Greef J (2005) Metabolomics in the context of systems biology: bridging traditional Chinese medicine and molecular pharmacology. Phytother Res 19:173-182 (Pubitemid 40827637)